The CARI guidelines. Calcineurin inhibitors in renal transplantation: the addition of anti-CD25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients.
Webster
Angela C
AC
Department of Renal Medicine, Royal Infirmary of Edinburgh, Old Dalkeith Road, Edinburgh EH16 4SY, UK. angela.webster@gmail.com
D000906:Antibodies / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D053264:B-Cell Activating Factor / Q000276:immunology*; D000077552:Basiliximab; D065095:Calcineurin Inhibitors; D000077561:Daclizumab; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*
D000906:Antibodies; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053264:B-Cell Activating Factor; D065095:Calcineurin Inhibitors; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D000077561:Daclizumab